WebApr 3, 2024 · OncoSec's lead immunotherapy investigational product candidate – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The therapeutic approach TAVO™-EP, which employs electroporation, is designed to produce a localized ... WebJan 20, 2024 · Rounding out the slate of major upcoming trial readouts is OncoSec’s tavokinogene telseplasmid for metastatic melanoma. The 143-patient Keynote-695 study ( NCT03132675 ), which has Merck listed as a collaborator, has topline primary endpoint results expected in Q1 2024.
OncoSec’s TAVO potential in TNBC depends on administration operability
WebApr 11, 2024 · Tavokinogene telseplasmid enables the intratumoral delivery of IL-12, a naturally occurring protein with immune-stimulating functions. Investigators believe that … WebJun 26, 2024 · This is a Phase 2, Multi-Cohort, Open-Label, Multi-Center Study. Cohort 1 will be a single-arm study of intratumoral tavokinogene telseplasmid (tavo) plus … stroud jewish community
ONCOSEC MEDICAL INC : Aktionäre Vorstände Geschäftsführer …
WebIntroduction: Tavokinogene Telseplasmid Electroporation Therapy (TAVO) and Pembrolizumab therapy is being studied in subjects with immune checkpoint inhibitor (ICI) resistant melanoma. TAVO is a novel office-based local therapy shown to be effective in patients with advanced melanoma. The technique involves the direct injection of a … WebNov 11, 2024 · Nov 11, 2024. Nichole Tucker. In Partnership With. The strategy of adding the plasmid IL-12 agent tavokinogene telseplasmid to pembrolizumab led to deep systemic responses in patients with actively progressing anti–PD-1–refractory advanced melanoma, according to interim results from the KEYNOTE-695 clinical trial. WebDec 19, 2024 · OncoSec Medical’s tavokinogene telseplasmid’s (TAVO’s) potential in triple-negative breast cancer (TNBC) relies on ironing out operability unknowns, experts said. However, local administration in combination with SOC has piqued some interest. TAVO is a plasmid-based interleukin (IL)-12 to be administered locally at the tumor site … stroud kids camp